- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06686615
Un estudio de ácido bempedoico en combinación con ezetimiba y rosuvastatina o atorvastatina en pacientes con hipercolesterolemia primaria o dislipidemia mixta (TRICONOS)
Efectividad y seguridad del ácido bempedoico en combinación con ezetimiba y rosuvastatina o atorvastatina en pacientes con hipercolesterolemia primaria o dislipidemia mixta: un estudio observacional
Data on the real-world use and effectiveness and safety of bempedoic acid combined with both a statin and ezetimibe in clinical practice is limited. There is an increased focus on using combination therapy to lower LDL-C.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The aim of the current study is to evaluate the effectiveness and safety of bempedoic acid combined with ezetimibe and either atorvastatin or rosuvastatin (hereafter defined as triple therapy) in a real-world clinical setting. No drug will be administered during this observational study.
The primary objective of the study is to evaluate the effectiveness of the triple therapy in terms of LDL-C reduction at 8 weeks.
The secondary objectives will include the following:
- Goal attainment at 8 weeks and 1 year after start of triple therapy
- Effectiveness of triple therapy in terms of LDL-C reduction at 1 year
- Effectiveness of adding bempedoic acid to statin and ezetimbe at 8 weeks and 1 year
- Effectiveness of adding bempedoic acid/ezetimibe FDC to statin in terms of LDL-C reduction at 8 weeks and 1 year
- Changes in laboratory values at 8 weeks and 1 year after start of triple therapy
- Adherence to triple therapy treatment
- Collection and recording of all adverse events occurred since initiation of triple therapy
- MACE-3 and MACE-4 (consisting of non-fatal MI, non-fatal stroke, CV-death, and coronary revascularization (for MACE-4 only)) during the year of follow-up
- Treatment changes at LMT initiation and at triple therapy initiation
- Treatment pathway from triple therapy initiation to 1-year after start of triple therapy
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Aachen, Alemania, 52062
- Praxis für Kardiologie Aachen
-
Ahaus, Alemania, 48683
- Klinikum Ahaus
-
Alsfed, Alemania, 36304
- Praxis W. Almohamed
-
Bad Homburg, Alemania, 61348
- Zentrum für klinische Studien Bad Homburg
-
Berlin, Alemania, 12627
- Dialysezentrum Hellersdorf Mitte
-
Berlin, Alemania, 13353
- Lipidambulanz Charite Campus Virchow
-
Burg, Alemania, 03096
- MEDICLIN Reha-Zentrum Spreewald
-
Chemnitz, Alemania, 09116
- Kardiologische Gemeinschaftspraxis Flemmingstr.
-
Detmold, Alemania, 32756
- Klinik Detmold
-
Dresden, Alemania, 01159
- Praxis Dr. Methfessel
-
Dresden, Alemania, 01796
- Cardiologicum Dresden
-
Goslar, Alemania, 38640
- Herz- und Gefäßmedizin Goslar
-
Greiz, Alemania, 07973
- Praxis
-
Gräfenhainichen, Alemania, 06773
- ndgl.; viele Kombinationstherapien
-
Hamburg, Alemania, 22459
- Kardiologie am Tibarg
-
Hasselt, Alemania, 3500
- Jessa Ziekenhuis
-
Heidelberg, Alemania, 69115
- HPK Heidelberger Praxisklinik
-
Heidelberg, Alemania, 69120
- Uni-Klinik Heidelberg
-
Kaiserslautern, Alemania, 67655
- Kardiopraxis
-
Koblenz, Alemania, 56073
- GK Mittelrhein
-
Konstanz, Alemania, 78464
- Klinikum Konstanz
-
Leipzig, Alemania, 04103
- Universitätsklinikum Leipzig
-
Lichtenstein, Alemania, 09350
- DRK Krankenhaus Lichtenstein Gemeinnützige GmbH
-
Ludwigsburg, Alemania, 71634
- Cardio Centrum Ludwigsburg
-
Mainz, Alemania, 55122
- Kardiopraxis
-
Markkleeberg, Alemania, 04416
- Kardiologische Praxis Markkleeberg
-
Moers, Alemania, 47441
- Kardiologie Gem. Praxis Dres Reiff/Linse/Haj-Yehia/Specking
-
Mühldorf A. Inn, Alemania, 84453
- Praxis Dr. Norbert Schön
-
Papenburg, Alemania, 26871
- Kardiologische Gemeinschaftspraxis Papenburg
-
Papenburg, Alemania, 26871
- Kardiologische Gemeinschaftpraxis Papenburg
-
Pirna, Alemania, 01796
- Hausärztlich-kardiologisches MVZ,,Am Felsenkeller" GmbH
-
Potsdam, Alemania, 14469
- Kardiologische Gemeinschaftspraxis am Park Sanssouci
-
Regensburg, Alemania, 93053
- Lipidambulanz Uniklinikum Regensburg
-
Stanhsdorf B. Berlin, Alemania, 14532
- Parkkardiologie, kard. Gemeinschaftspraxis
-
Trier, Alemania, 54292
- Diabetologische Schwerpunktpraxis
-
Trier, Alemania, 54292
- BBT Trier
-
Ulm, Alemania, 89077
- Herzklinik
-
Wuppertal, Alemania, 42103
- Dialysezentrum Hofaue
-
-
-
-
-
Braunau am Inn, Austria, 5280
- Innere Medizin
-
Feldkirch, Austria, 6800
- Innere Medizin 1
-
Graz, Austria, 8036
- Uniklinik Graz, Endokrinologie und Diabetes
-
Graz, Austria, 8036
- Uniklinik Graz, Kardiologie
-
Innsbruck, Austria, 6020
- Innere Medizin 3 - Kardiologie
-
Kepler Universitätsklinikum Gmb+, Austria, 4600
- Klinikum Wels-Grieskirchen GmbH+B18
-
Klagenfurt, Austria, 9020
- Innere Medizin
-
Linz, Austria, 4020
- Innere Medizin
-
Linz, Austria, 4021
- Kepler Universitätsklinikum GmbH Klinik für Innere Medizin 1 - Kardiologie und Internistische Intensivmedizin
-
Linz, Austria, 4040
- Kardiologie-Urfahr Dr. Hönig & Dr. Gammer & Dr. Buchmayr
-
Mattersburg, Austria, 7210
- Ordination
-
Mistelbach, Austria, 2130
- Landesklinikum Mistelbach - Gänserndorf
-
Saint Stefan Bei Graz, Austria, 8511
- Ordination Dr. med. univ. Evelyn Fließer-Görzer
-
Salzburg, Austria, 5020
- Praxis Gesundheitszentrum Moos 15 (Praxis Prof. Lichtenauer)
-
Salzburg, Austria, 5026
- DOZ (Dialyse- und Ordinationszentrum) Privatklinik Wehrle-Diakonissen
-
Vienna, Austria, 1090
- AKH Wien
-
Vienna, Austria, 1060
- Zentrum für Klinische Studien Dr. Hanusch GmbH
-
Vienna, Austria, 1030
- Klinik Landstrasse, Kardiologie
-
Vienna, Austria, 1060
- Ordination Univ.-Prof. Dr. Kurt Huber
-
Vienna, Austria, 1090
- Meduni Wien, Endokrinologie und Diabetes
-
Vienna, Austria, 1090
- Meduni Wien, Kardiologie
-
Vienna, Austria, 1130
- Clinic Hietzing
-
Vienna, Austria, 1180
- Herzzentrum 18
-
Vienna, Austria, 1210
- Karl Landsteiner Institut für kardiovaskuläre und intensivmedizinische Forschung c/o Abteilung für Kardiologie, Klinik Floridsdorf
-
-
-
-
-
Aalst, Bélgica, 9300
- Azorg
-
Antwerp, Bélgica, 2650
- UZA (Antwerp University Hospital)
-
Boussu, Bélgica, 7301
- Epicure Hornu
-
Brasschaat, Bélgica, 2930
- A.Z. KLINA Brasschaat
-
Bruges, Bélgica, 8400
- Algemeen Ziekenhuis Sint-Jan Oostende
-
Brussels, Bélgica, 1090
- UZ Brussel
-
Brussels, Bélgica, 1020
- CHU Brugman
-
Charleroi, Bélgica, 6042
- CHU Charleroi Hopital civil Marie-Curie
-
Charleroi, Bélgica, 6060
- GHDC Charleroi - Site Hôpital Saint-Joseph
-
Genk, Bélgica, 3600
- Z.O.L - Campus St. Jan
-
Ghent, Bélgica, 9000
- UZ Gent
-
Ghent, Bélgica, 9000
- Az Sint Lucas
-
Huy, Bélgica, 4500
- CHR Huy
-
Kortrijk, Bélgica, 8500
- AZ Groeninge Kortrijk
-
La Louvrière, Bélgica, 7100
- Pôle hospitalier Jolimont
-
Leper, Bélgica, 8900
- JAN YPERMAN Ziekenhuis
-
Leuven, Bélgica, 3000
- UZ Leuven
-
Liège, Bélgica, 4000
- CHR Citadelle de Liège
-
Mons, Bélgica, 7000
- CHU Mons Ambroise Paré
-
Roeselare, Bélgica, 8800
- AZ Delta
-
Ronse, Bélgica, 9600
- AZ Glorieux
-
Yvoir, Bélgica, 5530
- CHU UCL Mont-Godinne
-
-
-
-
-
Albacete, España, 02006
- H. Univers. De Albacete
-
Alicante, España, 03010
- Hospital General Universitario Dr. Balmis
-
Alicante, España, 03203
- H. General de Elche
-
Alicante, España, 03550
- Hospital Universitario de San Juan
-
Barakaldo, España, 48903
- Hospital Universitario de Cruces
-
Burgos, España, 09006
- Hospital Universitario de Burgos
-
Cadiz, España, 11510
- Hospital Universitario Puerto Real
-
Cadiz, España, 11009
- H. Univ. Puerta del Mar
-
Cadiz, España, 11207
- H. Punta de Europa
-
Cantabria, España, 39300
- Sierrallana Hospital
-
Córdoba, España, 14004
- H. Univ. Reina Sofía
-
Donostia / San Sebastian, España, 20014
- Hospital Universitario de Donostia
-
Gijón, España, 33394
- H. Univ. De Cabueñes
-
Granada, España, 18014
- H. Virgen de las Nieves
-
Huelva, España, 21005
- H. Juan Ramón Jiménez
-
Jaén, España, 23007
- Hospital Universitario Médico-Quirúrgico de Jaén
-
Las Palmas de GC, España, 35010
- Hospital Universitario de Gran Canarias Dr. Negrín
-
León, España, 24008
- Hospital de León
-
Logroño, España, 26006
- Hospital San Pedro
-
Marbella (Málaga), España, 29603
- H. Costa del Sol
-
Murcia, España, 30003
- Hospital General Universitario Reina Sofía
-
Murcia, España, 30120
- H. Virgen de la Arrixaca
-
Málaga, España, 29010
- H. Virgen de la Victoria
-
Málaga, España, 29400
- Hospital Serranía de Ronda
-
Oviedo, España, 33011
- Hospital Universitario Central de Asturias
-
Palma de Mallorca, España, 07198
- Hospital Universitario Son LLatzer
-
Pamplona, España, 31008
- Hospital Universitario de Navarra
-
Pamplona, España, 31008
- Clínica Universidad de Navarra
-
Santa Cruz de Tenerife, España, 38320
- Hospital Universitario de Canarias
-
Segovia, España, 40002
- Hospital de Segovia
-
Toledo, España, 45007
- Hospital General Universitario de Toledo
-
Valencia, España, 46026
- Hospital La Fe
-
Valencia, España, 46010
- H. Clínico Univ. De Valencia
-
Valencia, España, 46014
- Consorcio Hospital General Univ de Valencia
-
Vitoria-Gasteiz, España, 01009
- Hospital Universitario de Álava
-
Zaragoza, España, 50009
- Hospital Clinico Universitaro Lozano Blesa
-
-
-
-
-
Acquaviva delle Fonti, Italia, 70021
- Ente Ecclesiastico "Miulli"
-
Ancona, Italia, 60127
- INRCA
-
Avellino, Italia, 83100
- AO Moscati
-
Bari, Italia, 70123
- Osp. "San Paolo"
-
Bolzano, Italia, 39100
- Ospedale di Bolzano
-
Brescia, Italia, 25123
- Spedali Civili di Brescia
-
Casale Monferrato, Italia, 15033
- Osp. santo spirito
-
Caserta, Italia, 81100
- Ospedale Sant'Anna e san Sebastiano
-
Catanzaro, Italia, 88100
- Policlinnico Mater Domini
-
Chieti, Italia, 66100
- Osp. SS Annunziata
-
Enna, Italia, 94100
- PO Nuovo Umberti I
-
Ferrara, Italia, 44124
- Osp. Sant'Anna di Cona
-
Foggia, Italia, 71122
- Policlinico "Riuniti"
-
Genova, Italia, 16132
- Policlinico San Martino
-
Grosseto, Italia, 58100
- Osp della Misericordia
-
Lecce, Italia, 73100
- Osp. "Vito Fazzi"
-
Legnagno, Italia, 37045
- Ospedale Mater Salutis
-
Livorno, Italia, 57124
- Spedali Riuniti
-
Mantua, Italia, 46100
- Ospedale di Mantova
-
Messina, Italia, 98124
- Policlinico G. Martino
-
Milan, Italia, 20138
- IRCCS Monzino
-
Milan, Italia, 20157
- IRCCS Galeazzi Sant'Ambrogio
-
Modena, Italia, 41125
- Policlinico Modena
-
Naples, Italia, 80131
- AO Cardarelli
-
Naples, Italia, 80131
- Policlinico Federico II
-
Naples, Italia, 80138
- AOU Vanvitelli, I Policlinico
-
Palermo, Italia, 90127
- Policlinico P. Giaccone
-
Pavi, Italia, 27100
- ICS Maugeri
-
Perugia, Italia, 06129
- S. Maria della Misericordia
-
Pescara, Italia, 65124
- Presidio Ospedaliero
-
Peschiera, Italia, 37019
- Ospedale PederzoliItlit
-
Pisa, Italia, 56124
- Cisanello
-
Ravenna, Italia, 48121
- Osp. Santa Maria delle Croci
-
Rivoli, Italia, 10098
- Osp infermi di rivoli
-
Roma, Italia, 00133
- Policlinico Tor Vergata
-
Roma, Italia, 00157
- Ospedale Pertini
-
Roma, Italia, 00189
- Ospedale Sant'Andrea
-
Rome, Italia, 00161
- Policlinico Umberto I
-
Torino, Italia, 10128
- Ospedale Mauriziano
-
Torino, Italia, 10126
- Molinette Università to
-
Trieste, Italia, 34149
- Osp. di Cattinara
-
Venezia, Italia, 30026
- Ospedale di Portogruaro
-
Verona, Italia, 37126
- AOUI Verona
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Prospective data from routine clinical practice will be collected over the course of 1 year involving approximately 2000 patients across approximately 200 sites in Europe (Germany, Italy, Spain, Austria, and Belgium) treated by both specialized and non-specialized physicians in hospital and office-based settings.
Descripción
Key Inclusion Criteria:
-
Written informed consent to participate
-
At least 18 years of age
-
High and very high risk patients as assessed by the physician suffering from documented primary hypercholesterolemia or mixed dyslipidemia at start of bempedoic acid treatment
-
Patients treated with:
- bempedoic acid added to ezetimibe and rosuvastatin or atorvastatin,
- bempedoic acid plus ezetimibe added to rosuvastatin or atorvastatin,
- bempedoic acid plus atorvastatin or rosuvastatin added to ezetimibe
- initiation of bempedoic acid, ezetimibe, and atorvastatin or rosuvastatin simultaneously
6) Initiation of triple therapy within a maximum of four weeks prior to inclusion 7) An untreated LDL-C value must be available within 5 years prior to the start of the triple therapy. Untreated means that the LDL-C value is not influenced by any lipid lowering therapy at the time of blood collection. Time window for not being treated as specified in the protocol.
8) No contraindications exist according to the SmPC of bempedoic acid, the respective statin and ezetimibe as per physicians' assessment 9) No concurrent participation in an interventional study (simultaneous participation in other non-interventional studies is possible) 10) Life expectancy > 1 -year
Key Exclusion Criteria:
- Patients who have received PCSK9i monoclonal antibody treatment in the last 3 months before the start of the triple therapy exposure
- Patients who have ever received PCSK9i-siRNA treatment
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Triple therapy
Adult patients who have been diagnosed with primary hypercholesterolaemia (heterozygous familial and nonfamilial) or mixed dyslipidaemia treated with bempedoic acid in combination with ezetimibe and either rosuvastatin or atorvastatin (ie, triple therapy) and will be followed for up to 1 year after initiation of triple therapy. A direct comparison between rosuvastatin and atorvastatin is not planned, only an assessment of triple therapy on LDL-C change in patients with primary hypercholesterolaemia. |
No drug was administered in this observational study. No drug was administered in this observational study. No drug was administered in this observational study. No drug was administered in this observational study. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Relative LDL-C change between untreated and 8 week after triple therapy start
Periodo de tiempo: Baseline to 8 weeks after initiation of triple therapy
|
LDL-C will be assessed using a standard lipid panel blood test, |
Baseline to 8 weeks after initiation of triple therapy
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Proportion of patients at ESC/EAS 2019 dyslipidemia guideline goal at 8 weeks and 1 year
Periodo de tiempo: Baseline to 1 year after initiation of triple therapy
|
The 2019 EAS/ESC guidelines recommend treatment targets of at least a 50% reduction from baseline LDL-C levels and an LDL-C concentration below 1.8 mmol/L for patients at high and 1.4 mmol/l for patients at very high cardiovascular risk. |
Baseline to 1 year after initiation of triple therapy
|
|
Relative LDL-C change between untreated and 1 year after triple therapy start
Periodo de tiempo: From any prior LMT exposure to 1 year after initiation of triple therapy
|
LDL-C will be assessed using a standard lipid panel blood test, |
From any prior LMT exposure to 1 year after initiation of triple therapy
|
|
Relative LDL-C change between pre-bempedoic acid/pre-FDC initiation and 8 weeks after triple therapy start
Periodo de tiempo: From pre-bempedoic acid/pre-FDC initiation to 8 weeks after initiation of triple therapy
|
LDL-C will be assessed using a standard lipid panel blood test, |
From pre-bempedoic acid/pre-FDC initiation to 8 weeks after initiation of triple therapy
|
|
Relative LDL-C change between pre-bempedoic acid/pre-FDC initiation and 1 year after triple therapy start
Periodo de tiempo: From pre-bempedoic acid/pre-FDC initiation to 1 year after initiation of triple therapy
|
LDL-C will be assessed using a standard lipid panel blood test, |
From pre-bempedoic acid/pre-FDC initiation to 1 year after initiation of triple therapy
|
|
Relative change in laboratory values between triple therapy start and 8 weeks and 1 year thereafter
Periodo de tiempo: Baseline to 1 year after initiation of triple therapy
|
Labs will be assessed using a standard panel blood test, |
Baseline to 1 year after initiation of triple therapy
|
|
Patient and physician reported adherence at 8 weeks and 1 year after triple therapy start
Periodo de tiempo: Baseline to 1 year after initiation of triple therapy
|
Adherence will be judged by the physician/patient. |
Baseline to 1 year after initiation of triple therapy
|
|
Incidence of adverse events under triple therapy exposure
Periodo de tiempo: Baseline to 1 year after initiation of triple therapy
|
Adverse events are defined as any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. |
Baseline to 1 year after initiation of triple therapy
|
|
Proportion of patients with MACE-3 and MACE-4 events
Periodo de tiempo: Baseline to 1 year after initiation of triple therapy
|
MACE-3 and MACE-4 events will consist of non-fatal MI, non-fatal stroke, CV-death, and coronary revascularization (for MACE-4 only). |
Baseline to 1 year after initiation of triple therapy
|
Colaboradores e Investigadores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Compuestos de azufre
- Químicos orgánicos
- Compuestos heterocíclicos, 1 anillo
- Compuestos heterocíclicos
- Ácidos grasos
- Lípidos
- Azoles
- Hidrocarburos
- Amidas
- Pirimidinas
- Hidrocarburos, halogenados
- Pirroles
- Ácidos heptanoicos
- Sulfonamidas
- Sulfonas
- Azetidinas
- Azetín
- Fluorobencenos
- Hidrocarburos, fluorado
- Atorvastatina
- Rosuvastatina Cálcica
- Ezetimiba
- Ácido 8-hidroxi-2,2,14,14-tetrametilpentadecanodioico
Otros números de identificación del estudio
- DSE-BMP-01-24-EU
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .